<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:03:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9207753" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9207753</identifier>
        <datestamp>2022-06-29</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9207753</article-id>
              <article-id pub-id-type="pmcid">PMC9207753</article-id>
              <article-id pub-id-type="pmc-uid">9207753</article-id>
              <article-id pub-id-type="pmid">35715184</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2021-052043</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2021-052043</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Obstetrics and Gynaecology</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-48456129" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Hugh</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87660069" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1256-8723</contrib-id>
                  <name>
                    <surname>Li</surname>
                    <given-names>Howard J</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87660074" contrib-type="author">
                  <name>
                    <surname>Carson</surname>
                    <given-names>Sandra</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87660075" contrib-type="author">
                  <name>
                    <surname>Flores</surname>
                    <given-names>Valerie</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-59691482" contrib-type="author">
                  <name>
                    <surname>Pal</surname>
                    <given-names>Lubna</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87660077" contrib-type="author">
                  <name>
                    <surname>Robbins</surname>
                    <given-names>Jared</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-82391724" contrib-type="author">
                  <name>
                    <surname>Santoro</surname>
                    <given-names>Nanette F</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-84024965" contrib-type="author">
                  <name>
                    <surname>Segars</surname>
                    <given-names>James H</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-79682518" contrib-type="author">
                  <name>
                    <surname>Seifer</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-51570270" contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Hao</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-87660082" contrib-type="author">
                  <name>
                    <surname>Young</surname>
                    <given-names>Steven</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-38593764" contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Heping</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Obstetrics, Gynecology &amp; Reproductive Sciences</institution>, <institution>Yale School of Medicine</institution>, <addr-line content-type="city">New Haven</addr-line>, <addr-line content-type="state">Connecticut</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Obstetrics and Gynecology</institution>, <institution>Northwestern University</institution>, <addr-line content-type="city">Evanston</addr-line>, <addr-line content-type="state">Chicago</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Obstetrics and Gynecology</institution>, <institution>University of Colorado</institution>, <addr-line content-type="city">Denver</addr-line>, <addr-line content-type="state">Colorado</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Gynecology and Obstetrics</institution>, <institution>Johns Hopkins University School of Medicine</institution>, <addr-line content-type="city">Baltimore</addr-line>, <addr-line content-type="state">Maryland</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Biostatistics</institution>, <institution>Yale University School of Public Health</institution>, <addr-line content-type="city">New Haven</addr-line>, <addr-line content-type="state">Connecticut</addr-line>, <country>USA</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Obstetrics and Gynecology</institution>, <institution>The University of North Carolina</institution>, <addr-line content-type="city">Chapel Hill</addr-line>, <addr-line content-type="state">North Carolina</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Hugh Taylor; <email>hugh.taylor@yale.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <volume>12</volume>
              <issue>6</issue>
              <elocation-id>e052043</elocation-id>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>01</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2022-06-16">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2021-052043.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2021-052043.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2021-052043.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Infertility is a common complication of endometriosis. While in vitro fertilisation-embryo transfer (IVF) successfully treats endometriosis-associated infertility, there is some evidence that pregnancy rates may be diminished in women seeing fertility treatment for endometriosis-associated infertility compared with other etiologies of infertility. The use of gonadotropin releasing hormone (GnRH) agonist prior to IVF has been suggested to improve success, however studies have been small and rarely reported live birth rates. Recent approval of an oral GnRH antagonist for endometriosis provides a novel option for women with endometriosis who are undergoing IVF. There have been no studies on the efficacy of GnRH antagonists for the treatment of endometriosis-related infertility.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>This study is a multicentre, prospective, randomised, double-blind, placebo-controlled trial to study the efficacy of GnRH antagonist pretreatment for women with endometriosis who are undergoing IVF. A total of 814 patients with endometriosis undergoing fertility treatment will be enrolled and randomised 1:1 into two groups: elagolix 200 mg two times per day or placebo for 8 weeks, prior to undergoing IVF. All participants will then undergo IVF treatment per local protocols. The primary outcome is live birth. Secondary outcomes include oocyte number, fertilisation rate, embryo morphology and implantation rates, as well as rates of known endometriosis-related obstetrical outcomes (pregnancy-induced hypertension, antepartum haemorrhage, caesarean delivery and preterm birth).</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The PREGnant trial was approved by the Institutional Review Board at Johns Hopkins University. Results will be published in a peer-reviewed journal.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT04173169" ext-link-type="uri" specific-use="clinicaltrial results">NCT04173169</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Sex steroids &amp; HRT</kwd>
                <kwd>Subfertility</kwd>
                <kwd>Reproductive medicine</kwd>
                <kwd>Clinical trials</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R01HD100336</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>Limited evidence suggests that pretreatment with gonadotropin releasing hormone (GnRH) agonists may improve in vitro fertilisation (IVF) outcomes in patients with endometriosis; however, the recently available oral GnRH antagonist has not yet been studied for this purpose.</p>
                </list-item>
                <list-item>
                  <p>This study is a multicentre, prospective, randomised, double-blind, placebo-controlled study, randomising 814 patients with endometriosis undergoing fertility treatment 1:1 to elagolix 200 mg two times per day or placebo for 8 weeks prior to undergoing IVF.</p>
                </list-item>
                <list-item>
                  <p>This study uses a selective inclusion criteria requiring a documented diagnosis of endometriosis via direct surgical visualisation or standardised sonographical evidence.</p>
                </list-item>
                <list-item>
                  <p>Participants will undergo routine IVF protocols at each study site, improving the generalisability of results.</p>
                </list-item>
                <list-item>
                  <p>Participants will not be stratified by endometriosis severity or treatment history, and both fresh and frozen embryo transfers will be included in this study, which is not powered to detect differences in effect within these clinical subgroups.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Endometriosis is a disease of ectopic endometrial glands outside the uterus, commonly involving the adnexa and pelvic peritoneum. In addition to being a common cause of chronic pelvic pain, endometriosis is also associated with poorer reproductive outcomes. While endometriosis affects 10%–15% of reproductive aged women,<xref rid="R1" ref-type="bibr">1 2</xref> it is present in 25%–50% of women with infertility and conversely, 30%–50% of women with endometriosis struggle with infertility.<xref rid="R3" ref-type="bibr">3</xref> The fecundity of normal reproductive age couples without infertility is estimated to be around 15%–20% per month, while the fecundity of women with untreated endometriosis is estimated at 2%–10%.<xref rid="R4" ref-type="bibr">4 5</xref> Women with mild endometriosis have a significantly lower probability of pregnancy over 3 years compared with women with unexplained fertility (36% vs 55%, respectively).<xref rid="R6" ref-type="bibr">6</xref> Endometriosis is also associated with obstetrical complications, including obstetrical haemorrhage, caesarean delivery, pre-eclampsia and pregnancy-induced hypertension, and preterm birth.<xref rid="R7" ref-type="bibr">7–12</xref> While the mechanism remains controversial and unclear, endometriosis is thought to contribute to reduced fertility via adnexal scarring and poor endometrial receptivity, though studies also suggest with women with advanced endometriosis also have poor ovarian reserve, low oocyte and embryo quality, and poor implantation.<xref rid="R1" ref-type="bibr">1 13–15</xref></p>
              <p>Multiple effective treatments exist for the management of endometriosis-associated infertility, including laparoscopic destruction of endometriotic disease, ovulation induction and intrauterine insemination.<xref rid="R1" ref-type="bibr">1 16 17</xref> While some studies show that conservative treatment alone may be effective in improving fertility for women with endometriosis and potentially helps avoid obstetrical complications associated with in vitro fertilisation (IVF),<xref rid="R17" ref-type="bibr">17</xref> IVF remains the most direct and effective treatment for endometriosis-associated infertility, especially in patients who have failed conservative interventions.</p>
              <p>There is some evidence that endometriosis is also associated with poorer IVF outcomes, though this is controversial. One meta-analysis from 2002 including 22 non-randomised trials reported that the chances of achieving pregnancy with IVF in women with endometriosis was almost half that of those with tubal infertility (OR 0.56, 95% CI 0.44 to 0.7) and women with severe disease had about half the pregnancy rate of those with mild disease.<xref rid="R18" ref-type="bibr">18</xref> A more recent study published in 2018 showed via retrospective comparison of 531 women with endometriosis and 737 women with unexplained subfertility found that women with endometriosis still have a 24% lower likelihood of live birth after IVF than women with unexplained infertility.<xref rid="R19" ref-type="bibr">19</xref> However, a larger retrospective study in 2017 comparing 3583 women with endometriosis and 18 833 women without endometriosis found that endometriosis was associated with fewer oocytes retrieved, but no significant difference in live birth rates.<xref rid="R20" ref-type="bibr">20</xref> Similarly, a metanalysis of 33 studies published in 2015 examined the effect of endometrioma on IVF/ intracytoplasmic sperm injection (ICSI) outcomes and also found that women with endometrioma had fewer oocytes retrieved, but similar live birth rates.<xref rid="R21" ref-type="bibr">21</xref> A large metanalysis of 78 studies published in 2014 also found a difference in number of oocytes retrieved but no significant difference in live birth rates between women with and without endometriosis.<xref rid="R22" ref-type="bibr">22</xref> It is important to note, however, that the effect of endometriosis on IVF outcomes may be underestimated, especially in more recent studies, due to a likely underdiagnosis of endometriosis in the IVF population as laparoscopy is no longer a routine practice in infertility evaluations.<xref rid="R4" ref-type="bibr">4</xref> As endometriosis commonly presents in conjunction with other infertility diagnoses (eg, male factor, tubal factor, diminished ovarian reserve), it has been suggested that endometriosis, when associated with other barriers to fertility, contributes to poorer IVF outcomes in the general IVF population, even if this effect is not seen with endometriosis in isolation.<xref rid="R23" ref-type="bibr">23</xref> This finding may be due to a primary effect of endometriosis on reproductive biology, but may also be secondary to epidemiological or iatrogenic factors associated with an endometriosis diagnosis: greater exposure to prior gynaecological surgery resulting in ovarian injury, diminished reserve, or impaired folliculogenesis),<xref rid="R24" ref-type="bibr">24–26</xref> or an effect of subsequent adhesive disease on the technical difficulty of oocyte retrievals. These factors, however, have not been well studied as potential mechanisms by which endometriosis may compromise IVF outcomes.</p>
              <p>As the association between endometriosis and poorer IVF outcomes remains biologically plausible despite mixed clinical evidence,<xref rid="R1" ref-type="bibr">1 13–15 23</xref> pretreatment with gonadotropin releasing hormone (GnRH) agonist therapy has been investigated as a method to improve IVF outcomes, though with mixed evidence. As a hormone-dependent disorder, medical management of symptomatic endometriosis has targeted ovarian oestrogen production, including combined oral contraceptives, progestins, danazol and GnRH agonists or antagonist.<xref rid="R27" ref-type="bibr">27</xref> While these therapies have been helpful in managing endometriosis-associated pelvic pain, they have not been shown to treat endometriosis-associated infertility in the absence of IVF.<xref rid="R5" ref-type="bibr">5</xref> In the IVF setting, prolonged GnRH agonist treatment prior to IVF has been shown by several studies to improve fertility rates in women with advanced endometriosis,<xref rid="R28" ref-type="bibr">28–30</xref> though a recent Cochrane review of 8 randomised controlled trials (RCTs) was unable to determine whether prolonged GnRH agonist treatment improved subsequent IVF outcomes, partly due to low quality of available evidence.<xref rid="R31" ref-type="bibr">31</xref></p>
              <p>Since then, the GnRH antagonist elagolix has recently become available for use, with a number of advantages over GnRH agonists: the convenience of oral rather than parenteral administration, improved tolerability and reduced severity of vasomotor symptoms, rapid onset of action with suppression of endogenous estradiol levels within 24 hours, and lack of initial gonadotropin stimulation (‘flare’ effect) seen with GnRH agonists.<xref rid="R32" ref-type="bibr">32</xref> However, elagolix has not yet been studied as an adjunctive treatment prior to IVF for women with endometriosis. Based on limited evidence from GnRH agonist trials, we hypothesise that GnRH antagonist therapy may potentially benefit women with endometriosis undergoing IVF treatment, possibly with a shorter course of treatment compared with what has been studied with GnRH agonists (3–6 months).<xref rid="R31" ref-type="bibr">31 33</xref></p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <p>This is a multicentre, prospective, RCT to study the effect of GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF.</p>
              <sec id="s2-1">
                <title>Participants</title>
                <p>Participants will be recruited based on the following inclusion criteria:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Women aged 18–38.</p>
                  </list-item>
                  <list-item>
                    <p>Planning to undergo a cycle of IVF for treatment of infertility.</p>
                  </list-item>
                  <list-item>
                    <p>Surgical or sonographical diagnosis of endometriosis.</p>
                  </list-item>
                  <list-item>
                    <p>Body mass index (BMI) 18–38 kg/m<sup>2</sup> (inclusive) at time of screening.</p>
                  </list-item>
                  <list-item>
                    <p>Anti-Mullerian hormone (AMH) &gt;0.8 ng/mL within 6 months of planned IVF cycle start.</p>
                  </list-item>
                  <list-item>
                    <p>Uterine cavity assessment by sonohysterogram or hysteroscopy within 6 months indicating adequacy for embryo transfer (ET).</p>
                  </list-item>
                  <list-item>
                    <p>Presence of at least one ovary with no clinically significant abnormalities (other than endometrioma).</p>
                  </list-item>
                  <list-item>
                    <p>Negative urine or cervical swab for gonorrhoea and chlamydia within 12 months of recruitment.</p>
                  </list-item>
                  <list-item>
                    <p>Willingness and ability to comply with trial procedures, including reporting of obstetrical outcomes after delivery.</p>
                  </list-item>
                </list>
                <p>A diagnosis of endometriosis must be confirmed by surgical visualisation of endometriosis (at the time of laparoscopy or laparotomy) within the last 10 years of initial trial visit, or by sonographical documentation of an ovarian endometrioma &gt;2 cm, or two or more smaller endometriomas that total &gt;2 cm in diameter. If a diagnosis of endometriosis was made sonographically, serial transvaginal ultrasounds must have documented the same unambiguous endometrioma on two separate occasions in more than one menstrual cycle. Images will be read centrally by the same investigator to assure uniform diagnostic criteria are applied.</p>
                <p>Women will be excluded from the study if there was:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Use of GnRH agonists or antagonists within 6 months of study start, except for antagonist use as part of an IVF cycle.</p>
                  </list-item>
                  <list-item>
                    <p>Use of depot medroxyprogesterone acetate (MPA) or subdermal contraceptive implant (eg, Implanon or Nexplanon) within 10 months of study start.</p>
                  </list-item>
                  <list-item>
                    <p>Continuous use of oral progestins (MPA, norethindrone acetate) within 3 months of study start.</p>
                  </list-item>
                  <list-item>
                    <p>Use of aromatase inhibitors, danazol or hormonal contraceptives (including combined contraceptive pill, progestin-only pill, transdermal patch or contraceptive ring) within 1 month of study start.</p>
                  </list-item>
                  <list-item>
                    <p>Pregnancy greater than 8 weeks in length within the last 6 months.</p>
                  </list-item>
                  <list-item>
                    <p>History of three or more prior IVF/ICSI attempts.</p>
                  </list-item>
                  <list-item>
                    <p>Presence of hydrosalpinx &gt;2 cm on ultrasound, untreated endometrial polyps, submucosal uterine leiomyomata or intrauterine adhesions.</p>
                  </list-item>
                  <list-item>
                    <p>Abnormal cervical cytology other than low grade within last year.</p>
                  </list-item>
                  <list-item>
                    <p>History of malignancy within 5 years of the start of screening, except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin.</p>
                  </list-item>
                  <list-item>
                    <p>History of suicide attempt within the last year of recruitment.</p>
                  </list-item>
                  <list-item>
                    <p>Hypersensitivity to study drugs.</p>
                  </list-item>
                  <list-item>
                    <p>Planned surgical treatment of endometriosis or planned surgery in the abdominal-pelvic area within the duration of the trial.</p>
                  </list-item>
                  <list-item>
                    <p>Untreated abnormal prolactin or thyroid stimulating hormone (TSH).</p>
                  </list-item>
                  <list-item>
                    <p>Presence of any condition for which pregnancy is precluded.</p>
                  </list-item>
                </list>
                <p>Participants will be recruited from the population of patients already committed to pursuing IVF at one of the five participating clinical centres in the trial (Yale University, University of Colorado-Denver, Northwestern University, Johns Hopkins and University of North Carolina). Additional clinical centres may be added for enrollment if needed. All participants will provide written, informed consent for their participation in this study (see <xref rid="SP1" ref-type="supplementary-material">online supplemental file</xref>). This study was approved by a central Institutional Review Boards (IRB) as well as local IRBs at all five participating centres. In addition, the Food and Drug Administration gave permission for the study to proceed using elagolix as an Investigational New Drug (152645) for this indication.</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2021-052043.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2021-052043supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-2">
                <title>Intervention</title>
                <sec id="s2-2-1">
                  <title>GnRH antagonist pretreatment</title>
                  <p>Participants will be randomised 1:1 into one of two treatment groups: GnRH antagonist (elagolix 200 mg two times per day) or placebo for 8 weeks, prior to undergoing IVF. While using GnRH antagonists, hot flashes and other vasomotor symptoms may occur. If indicated, use of paroxetine mesylate will be allowed. No sex steroids or other hormone modifying treatments are permitted. The GnRH antagonist will be administered during the routine evaluation conducted prior to the IVF cycle.</p>
                </sec>
                <sec id="s2-2-2">
                  <title>IVF treatment</title>
                  <p>All participants will then undergo IVF treatment per local protocols, with agreed on standards. All sites will use standard follicle stimulating hormone (FSH) stimulation and GnRH antagonist in each cycle with the exception that additional luteinizing hormone (LH) activity will always be supplied at the outset of stimulation, since half of the participants will have been on GnRH antagonist pre-treatment and will be expected to have suppressed LH. Non-conventional IVF therapies outside of those following standard protocols at each site will not be performed.</p>
                  <p>The standard IVF treatment for the study will be a GnRH antagonist protocol (cetrotide or ganirelix). Gonadotrophin stimulation with recombinant human follicle stimulating hormone and menotropin (supplying 75 IU FSH and 75 IU LH activity per vial) will be started at a daily dose ranging 150–375 IU depending on patient characteristics including age, early follicular phase FSH, AMH, antral follicle count and BMI. Each patient will receive at least 75 IU of LH activity daily as part of the initial stimulation protocol to counteract the LH suppression by the GnRH antagonist. The oral GnRH antagonist will be discontinued at the start of stimulation; addition of subcutaneous injections of GnRH antagonist will be based on each sites’ standard IVF protocol. When at least two leading follicles measuring ≥18 mm are seen on ultrasound, the trigger injection of u-human chorionic gonadotrophin (hCG) (10 000 IU) or r-hCG (250 mcg) is administered, followed by oocyte retrieval 37 hours later. Depending on sperm parameters following preparation on the day of oocyte retrieval, fertilisation will be achieved either by conventional IVF or ICSI.<xref rid="R34" ref-type="bibr">34</xref></p>
                </sec>
                <sec id="s2-2-3">
                  <title>Embryo culture and transfer</title>
                  <p>ET is performed between days 3 and 5 of development depending on morphological assessment and the woman’s age, following American Society for Reproductive Medicine (ASRM) guidelines allowing for transfer of up to two embryos, with an elective single ET preferred.<xref rid="R35" ref-type="bibr">35 36</xref> Preimplantation Genetic Testing for aneuploidy will be allowed. Frozen ETs are included in this study but must be preceded by the same pre-treatment with GnRH antagonist or placebo for 8 weeks, repeating the same treatment as initially assigned at randomisation. No more than two ETs will be performed under this protocol, limiting administration of study drug to a maximum of three 8 week courses (one prior to IVF and one prior to each ET).</p>
                  <p>Luteal support will be initiated 1 day after oocyte retrieval with intramuscular or vaginal micronised progesterone and continued for 14 days, when a urine pregnancy test is performed. If pregnant, luteal support is continued until 10 weeks of pregnancy. A transvaginal ultrasound scan is scheduled to confirm a viable intrauterine pregnancy and determine number of gestations. Women are then discharged from the care of the IVF unit to their obstetrician for further prenatal care and delivery. Participants will have been consented for access to comprehensive pregnancy outcome and birth data at the time of enrolment.</p>
                </sec>
              </sec>
              <sec id="s2-3">
                <title>Randomisation</title>
                <p>Eligible women will be randomised in a 1:1 fashion to one of two treatments:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Elagolix 200 mg two times per day daily for 8 weeks prior to undergoing IVF.</p>
                  </list-item>
                  <list-item>
                    <p>Placebo, two times per day daily for 8 weeks prior to undergoing IVF.</p>
                  </list-item>
                </list>
                <p>A computer-generated randomisation list will be created by staff at the PREGnant Data Coordinating Centre (DCC) and randomisation will be performed prior to the first dose of elagolix or placebo. Randomisation will have random sizes (2, 4 or 6) of blocks, stratified by site and age group (&lt;35 vs ≥35 years). Randomisation sequences within each study site and age stratum will be generated randomly and independently. The randomisation list will not be available to any person involved in the conduct and evaluation of the trial until the trial is complete and database is declared clean and is released by the DCC. Randomisation and treatment allocation will be initiated by study staff according to the randomisation list following enrolment and prior to the first dose of elagolix or placebo, but participants, investigators, trial staff and central laboratory personnel will be blinded to the treatment assignment during the trial duration (except for serious safety concerns). The assigned treatment (GnRH antagonist vs placebo) applied during the fresh cycle will also be used for subsequent frozen ETs resulting from the initial ‘fresh’ egg retrieval cycle. Most women using elagolix menstruate in the first 2 months with only a 50% amenorrhoea rate after 1 year in the phase III clinical trial, enabling blinding to remain intact.</p>
              </sec>
              <sec id="s2-4">
                <title>Outcome measures</title>
                <p>The primary outcome measure will be live birth rate per cycle start, defined as live birth at ≥24 weeks of gestation. As a secondary outcome measure, we will also analyse the live birth rate per ET.</p>
                <p>For exploratory analysis, we will examine a number of IVF cycle parameters: (1) Estradiol (E2) level on the day of hCG administration; (2) Progesterone (P) level on the day of hCG administration; (3) The number of oocytes retrieved; (4) Gonadotropin dosage and duration; (5) Number and per cent of mature metaphase II oocytes; (6) Fertilisation (2PN) rate; (7) Blastocyst rate; (8) Incidence of moderate-to-severe ovarian hyperstimulation syndrome; (9) Implantation rate; (10) Clinical pregnancy rate; (11) Miscarriage rate (defined as pregnancy loss prior to viability scan and including those confirmed on ultrasound scan up to ≤23 weeks 6 days gestation); (12) Rate of ectopic pregnancy or pregnancy of unknown location; (13) Ongoing pregnancy rate and (14) Multiple pregnancy rate.</p>
                <p>We will also measure pregnancy-related parameters to determine the effect of pretreatment with GnRH antagonist on pregnancy related complications associated with endometriosis: pre-eclampsia and pregnancy-induced hypertension, preterm birth, intrauterine growth restriction, caesarean delivery and obstetric haemorrhage.</p>
                <p>Finally, quality of life will be assed using the FertiQOL, a validated questionnaire that contains Emotional, Mind/Body, Relational and Social domains.<xref rid="R37" ref-type="bibr">37</xref></p>
              </sec>
              <sec id="s2-5">
                <title>Statistical analysis</title>
                <sec id="s2-5-1">
                  <title>Sample size and power calculations</title>
                  <p>The average live birth rate for women with endometriosis undergoing IVF is estimated to be 39%, based on 2016 SART data showing a live birth rate of 44.7% per cycle in women with endometriosis under the age of 35% and 34.0% in women ages 35–37. Using 386 participants per arm (n=772) would provide an alpha of 0.05 and power of 80% to detect an effect of 10% absolute improvement in live birth rate to 49% in the GnRH antagonist arm. This effect is conservatively estimated from prior randomised trials using GnRH agonists,<xref rid="R28" ref-type="bibr">28–30</xref> and what investigators deemed to be sufficient to recommend the routine use of GnRH antagonists in IVF protocols for this population. However, we acknowledge that the study may be underpowered to detect smaller but still relevant effects (5%–10% improvement). We will aim to enrol and randomise 814 participants (407 per treatment group), to account for an estimated drop-out rate of 5%.</p>
                </sec>
                <sec id="s2-5-2">
                  <title>Analysis of outcome measures</title>
                  <p>An intention-to-treat analysis will be performed on primary and secondary outcome measures. The primary outcome, cumulative live birth rate, will be compared between the two intervention arms using Pearson’s χ<sup>2</sup> test of independence. Baseline patient characteristics and secondary outcome measures will also be analysed with Pearson’s χ<sup>2</sup> test and logistic regression as needed.</p>
                  <p>Based on prior experience, we expect a data completion rate of at least 99.5% and we do not expect missing data to significantly affect trial analysis or results. In the unlikely event of unexpectedly high rates of missing data, the potential mechanisms for missing data (missing completely at random, missing at random or missing not at random) will be examined. We will compare the available characteristics of those with missing data to those with complete data. If necessary, imputation techniques may be used.</p>
                </sec>
              </sec>
              <sec id="s2-6">
                <title>Safety and adverse events monitoring</title>
                <p>The safety of the intervention medication elagolix has been previously investigated and found to be tolerable.<xref rid="R24" ref-type="bibr">24</xref> All adverse events are collected regardless of their grade of severity and reported based on established criteria. Data safety monitoring board (DSMB) will receive unblinded data and advise on potential safety issues. The choice of continuing therapy or trial participation based on adverse events is at the discretion of the investigator and DSMB determinations.</p>
              </sec>
              <sec id="s2-7">
                <title>Patient and public involvement</title>
                <p>Patients and the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </sec>
              <sec id="s2-8">
                <title>Ethics and dissemination</title>
                <p>The PREGnant trial was approved by the Institutional Review Board at Johns Hopkins University School of Medicine (JHM IRB) on 12 August 2021, application #IRB00236742, with reliance agreements at all participating sites.</p>
                <p>Protocol modifications will be reviewed by the IRB and reported to the funder. Participating investigators, providers and study staff will be informed of protocol changes via email. Significant protocol modifications will also be noted on ClinicalTrials.gov.</p>
                <p>Elagolix has had increasing use in treating endometriosis-related pain, and the findings of this trial can be easily adopted into the IVF setting. The results of this trial may reveal a new way to optimise outcomes for women with endometriosis seeking fertility treatment.</p>
                <p>The trial is conducted in accordance with relevant regulations and standard operating procedures, including data protection. Each subject is assigned a unique code for deidentification. Data will be collected electronically and abstracted from the electronic medical record in a deidentified manner. Any medical information that is obtained in connection with this programme that could identify a subject will remain confidential and will be disclosed only as required by law. All persons responsible for the quality control of the data take all necessary precautions to ensure the confidentiality of information regarding trial participants and in particular the identity of the participants and the results obtained. The final trial dataset will be available to study investigators and Research Ethic Boards at all participating sites. Results of the trial will be published in peer-reviewed journals. We will submit data and samples collected by the trial to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (DASH). The informed consent will include permission to bank these samples. The processes included initial data and documentation preparation (eg, codebooks, protocols, informed consent for data sharing), data quality control and submission.</p>
              </sec>
              <sec id="s2-9">
                <title>Trial status and registration</title>
                <p>The study was conceived and designed in 2019. Recruitment is expected to begin in December 2021. This study is registered on ClinicalTrials.gov Identifier NCT04173169. This manuscript describes the latest version, last updated on November 2021.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e229">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2021-052043.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e230">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2021-052043.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> HT, HJL, SC, VF, LP, JR, NFS, JHS, DS, HH, SY and HZ each made substantial contributions to the conception or design of the study protocol, design of the study intervention, study outcomes, study procedures and/or revised the protocol critically for important intellectual content and approved the final version to be published. HZ made substantial contributions to the conception or design of the study protocol and wrote the first draft of the protocol. HJL wrote the first draft of this manuscript. All authors approved the final version to be published.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This study was funded by a grant titled 'Pre-IVF treatment with a GnRH antagonist in women with endometriosis-A prospective double blind placebo controlled trial (PREGnant)' from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 1R01HD100336.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Macer</surname><given-names>ML</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility</article-title>. <source>Obstet Gynecol Clin North Am</source><year>2012</year>;<volume>39</volume>:<fpage>535</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.ogc.2012.10.002</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23182559?><pub-id pub-id-type="pmid">23182559</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname><given-names>HS</given-names></string-name>, <string-name><surname>Kotlyar</surname><given-names>AM</given-names></string-name>, <string-name><surname>Flores</surname><given-names>VA</given-names></string-name></person-group>. <article-title>Endometriosis is a chronic systemic disease: clinical challenges and novel innovations</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>:<fpage>839</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00389-5</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33640070?><pub-id pub-id-type="pmid">33640070</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verkauf</surname><given-names>BS</given-names></string-name>, <string-name><surname>Incidence</surname><given-names>VBS</given-names></string-name></person-group>. <article-title>Incidence, symptoms, and signs of endometriosis in fertile and infertile women</article-title>. <source>J Fla Med Assoc</source><year>1987</year>;<volume>74</volume>:<fpage>671</fpage>–<lpage>5</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/2961844?><pub-id pub-id-type="pmid">2961844</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Practice Committee of the American Society for Reproductive Medicine</collab></person-group>. <article-title>Endometriosis and infertility: a Committee opinion</article-title>. <source>Fertil Steril</source><year>2012</year>;<volume>98</volume>:<fpage>591</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2012.05.031</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22704630?><pub-id pub-id-type="pmid">22704630</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hughes</surname><given-names>EG</given-names></string-name>, <string-name><surname>Fedorkow</surname><given-names>DM</given-names></string-name>, <string-name><surname>Collins</surname><given-names>JA</given-names></string-name></person-group>. <article-title>A quantitative overview of controlled trials in endometriosis-associated infertility</article-title>. <source>Fertil Steril</source><year>1993</year>;<volume>59</volume>:<fpage>963</fpage>–<lpage>70</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/8486196?><pub-id pub-id-type="pmid">8486196</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akande</surname><given-names>VA</given-names></string-name>, <string-name><surname>Hunt</surname><given-names>LP</given-names></string-name>, <string-name><surname>Cahill</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Differences in time to natural conception between women with unexplained infertility and infertile women with minor endometriosis</article-title>. <source>Hum Reprod</source><year>2004</year>;<volume>19</volume>:<fpage>96</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/deh045</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/14688164?><pub-id pub-id-type="pmid">14688164</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Healy</surname><given-names>DL</given-names></string-name>, <string-name><surname>Breheny</surname><given-names>S</given-names></string-name>, <string-name><surname>Halliday</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence and risk factors for obstetric haemorrhage in 6730 singleton births after assisted reproductive technology in Victoria Australia</article-title>. <source>Hum Reprod</source><year>2010</year>;<volume>25</volume>:<fpage>265</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/dep376</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19897853?><pub-id pub-id-type="pmid">19897853</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takemura</surname><given-names>Y</given-names></string-name>, <string-name><surname>Osuga</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fujimoto</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Increased risk of placenta previa is associated with endometriosis and tubal factor infertility in assisted reproductive technology pregnancy</article-title>. <source>Gynecol Endocrinol</source><year>2013</year>;<volume>29</volume>:<fpage>113</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.3109/09513590.2012.706669</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22835092?><pub-id pub-id-type="pmid">22835092</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vercellini</surname><given-names>P</given-names></string-name>, <string-name><surname>Parazzini</surname><given-names>F</given-names></string-name>, <string-name><surname>Pietropaolo</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pregnancy outcome in women with peritoneal, ovarian and rectovaginal endometriosis: a retrospective cohort study</article-title>. <source>BJOG</source><year>2012</year>;<volume>119</volume>:<fpage>1538</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-0528.2012.03466.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22900995?><pub-id pub-id-type="pmid">22900995</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conti</surname><given-names>N</given-names></string-name>, <string-name><surname>Cevenini</surname><given-names>G</given-names></string-name>, <string-name><surname>Vannuccini</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Women with endometriosis at first pregnancy have an increased risk of adverse obstetric outcome</article-title>. <source>J Matern Fetal Neonatal Med</source><year>2015</year>;<volume>28</volume>:<fpage>1795</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3109/14767058.2014.968843</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/25262994?><pub-id pub-id-type="pmid">25262994</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fernando</surname><given-names>S</given-names></string-name>, <string-name><surname>Breheny</surname><given-names>S</given-names></string-name>, <string-name><surname>Jaques</surname><given-names>AM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preterm birth, ovarian endometriomata, and assisted reproduction technologies</article-title>. <source>Fertil Steril</source><year>2009</year>;<volume>91</volume>:<fpage>325</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2008.01.096</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18384780?><pub-id pub-id-type="pmid">18384780</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stephansson</surname><given-names>O</given-names></string-name>, <string-name><surname>Kieler</surname><given-names>H</given-names></string-name>, <string-name><surname>Granath</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome</article-title>. <source>Hum Reprod</source><year>2009</year>;<volume>24</volume>:<fpage>2341</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/dep186</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19439428?><pub-id pub-id-type="pmid">19439428</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matalliotakis</surname><given-names>IM</given-names></string-name>, <string-name><surname>Cakmak</surname><given-names>H</given-names></string-name>, <string-name><surname>Mahutte</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Women with advanced-stage endometriosis and previous surgery respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tubal factor infertility</article-title>. <source>Fertil Steril</source><year>2007</year>;<volume>88</volume>:<fpage>1568</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.01.037</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/17349642?><pub-id pub-id-type="pmid">17349642</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brosens</surname><given-names>I</given-names></string-name></person-group>. <article-title>Endometriosis and the outcome of in vitro fertilization</article-title>. <source>Fertil Steril</source><year>2004</year>;<volume>81</volume>:<fpage>1198</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2003.09.071</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15136075?><pub-id pub-id-type="pmid">15136075</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olivennes</surname><given-names>F</given-names></string-name></person-group>. <article-title>[Results of IVF in women with endometriosis]</article-title>. <source>J Gynecol Obstet Biol Reprod</source><year>2003</year>;<volume>32</volume>:<fpage>S45</fpage>–<lpage>7</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/14968069?></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Terzic</surname><given-names>M</given-names></string-name>, <string-name><surname>Aimagambetova</surname><given-names>G</given-names></string-name>, <string-name><surname>Garzon</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Ovulation induction in infertile women with endometriotic ovarian cysts: current evidence and potential pitfalls</article-title>. <source>Minerva Med</source><year>2020</year>;<volume>111</volume>:<fpage>50</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.23736/S0026-4806.19.06346-8</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31755673?><pub-id pub-id-type="pmid">31755673</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Šalamun</surname><given-names>V</given-names></string-name>, <string-name><surname>Verdenik</surname><given-names>I</given-names></string-name>, <string-name><surname>Laganà</surname><given-names>AS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Should we consider integrated approach for endometriosis-associated infertility as gold standard management? rationale and results from a large cohort analysis</article-title>. <source>Arch Gynecol Obstet</source><year>2018</year>;<volume>297</volume>:<fpage>613</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s00404-017-4633-0</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29274003?><pub-id pub-id-type="pmid">29274003</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barnhart</surname><given-names>K</given-names></string-name>, <string-name><surname>Dunsmoor-Su</surname><given-names>R</given-names></string-name>, <string-name><surname>Coutifaris</surname><given-names>C</given-names></string-name></person-group>. <article-title>Effect of endometriosis on in vitro fertilization</article-title>. <source>Fertil Steril</source><year>2002</year>;<volume>77</volume>:<fpage>1148</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0015-0282(02)03112-6</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/12057720?><pub-id pub-id-type="pmid">12057720</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muteshi</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ohuma</surname><given-names>EO</given-names></string-name>, <string-name><surname>Child</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effect of endometriosis on live birth rate and other reproductive outcomes in art cycles: a cohort study</article-title>. <source>Hum Reprod Open</source><year>2018</year>;<volume>2018</volume>:<elocation-id>hoy016</elocation-id>. <pub-id pub-id-type="doi">10.1093/hropen/hoy016</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30895257?><pub-id pub-id-type="pmid">30895257</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>González-Comadran</surname><given-names>M</given-names></string-name>, <string-name><surname>Schwarze</surname><given-names>JE</given-names></string-name>, <string-name><surname>Zegers-Hochschild</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The impact of endometriosis on the outcome of assisted reproductive technology</article-title>. <source>Reprod Biol Endocrinol</source><year>2017</year>;<volume>15</volume>:<fpage>8</fpage>. <pub-id pub-id-type="doi">10.1186/s12958-016-0217-2</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28118836?><pub-id pub-id-type="pmid">28118836</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamdan</surname><given-names>M</given-names></string-name>, <string-name><surname>Dunselman</surname><given-names>G</given-names></string-name>, <string-name><surname>Li</surname><given-names>TC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis</article-title>. <source>Hum Reprod Update</source><year>2015</year>;<volume>21</volume>:<fpage>809</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/humupd/dmv035</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26168799?><pub-id pub-id-type="pmid">26168799</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbosa</surname><given-names>MAP</given-names></string-name>, <string-name><surname>Teixeira</surname><given-names>DM</given-names></string-name>, <string-name><surname>Navarro</surname><given-names>PAAS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis</article-title>. <source>Ultrasound Obstet Gynecol</source><year>2014</year>;<volume>44</volume>:<fpage>261</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/uog.13366</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24639087?><pub-id pub-id-type="pmid">24639087</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Senapati</surname><given-names>S</given-names></string-name>, <string-name><surname>Sammel</surname><given-names>MD</given-names></string-name>, <string-name><surname>Morse</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database</article-title>. <source>Fertil Steril</source><year>2016</year>;<volume>106</volume>:<fpage>164</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2016.03.037</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27060727?><pub-id pub-id-type="pmid">27060727</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Legendre</surname><given-names>G</given-names></string-name>, <string-name><surname>Catala</surname><given-names>L</given-names></string-name>, <string-name><surname>Morinière</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Relationship between ovarian cysts and infertility: what surgery and when?</article-title><source>Fertil Steril</source><year>2014</year>;<volume>101</volume>:<fpage>608</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.01.021</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24559614?><pub-id pub-id-type="pmid">24559614</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alammari</surname><given-names>R</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>M</given-names></string-name>, <string-name><surname>Hur</surname><given-names>H-C</given-names></string-name></person-group>. <article-title>Impact of cystectomy on ovarian reserve: review of the literature</article-title>. <source>J Minim Invasive Gynecol</source><year>2017</year>;<volume>24</volume>:<fpage>247</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmig.2016.12.010</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28089684?><pub-id pub-id-type="pmid">28089684</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diamond</surname><given-names>MP</given-names></string-name>, <string-name><surname>Pellicer</surname><given-names>A</given-names></string-name>, <string-name><surname>Boyers</surname><given-names>SP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effect of periovarian adhesions on follicular development in patients undergoing ovarian stimulation for in vitro fertilization-embryo transfer</article-title>. <source>Fertil Steril</source><year>1988</year>;<volume>49</volume>:<fpage>100</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/S0015-0282(16)59657-5</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/3121395?><pub-id pub-id-type="pmid">3121395</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Practice Committee of the American Society for Reproductive Medicine</collab></person-group>. <article-title>Treatment of pelvic pain associated with endometriosis: a Committee opinion</article-title>. <source>Fertil Steril</source><year>2014</year>;<volume>101</volume>:<fpage>927</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2014.02.012</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24630080?><pub-id pub-id-type="pmid">24630080</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Surrey</surname><given-names>ES</given-names></string-name>, <string-name><surname>Silverberg</surname><given-names>KM</given-names></string-name>, <string-name><surname>Surrey</surname><given-names>MW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis</article-title>. <source>Fertil Steril</source><year>2002</year>;<volume>78</volume>:<fpage>699</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1016/S0015-0282(02)03373-3</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/12372443?><pub-id pub-id-type="pmid">12372443</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ozkan</surname><given-names>S</given-names></string-name>, <string-name><surname>Arici</surname><given-names>A</given-names></string-name></person-group>. <article-title>Advances in treatment options of endometriosis</article-title>. <source>Gynecol Obstet Invest</source><year>2009</year>;<volume>67</volume>:<fpage>81</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1159/000163071</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18931504?><pub-id pub-id-type="pmid">18931504</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>Y-hong</given-names></string-name>, <string-name><surname>Lu</surname><given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone</article-title>. <source>Contemp Clin Trials</source><year>2012</year>;<volume>33</volume>:<fpage>1206</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2012.07.009</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22820320?><pub-id pub-id-type="pmid">22820320</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Georgiou</surname><given-names>EX</given-names></string-name>, <string-name><surname>Melo</surname><given-names>P</given-names></string-name>, <string-name><surname>Baker</surname><given-names>PE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Long-Term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis</article-title>. <source>Cochrane Database Syst Rev</source><year>2019</year>;<volume>2019</volume>. <pub-id pub-id-type="doi">10.1002/14651858.CD013240.pub2</pub-id>. [Epub ahead of print: <comment>20 Nov 2019</comment>].<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31747470?></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname><given-names>HS</given-names></string-name>, <string-name><surname>Giudice</surname><given-names>LC</given-names></string-name>, <string-name><surname>Lessey</surname><given-names>BA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>28</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1700089</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28525302?><pub-id pub-id-type="pmid">28525302</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sallam</surname><given-names>HN</given-names></string-name>, <string-name><surname>Garcia-Velasco</surname><given-names>JA</given-names></string-name>, <string-name><surname>Dias</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Long-Term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis</article-title>. <source>Cochrane Database Syst Rev</source><year>2006</year>:<elocation-id>CD004635</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD004635.pub2</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16437491?><pub-id pub-id-type="pmid">16437491</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology</collab></person-group>. <source>Intracytoplasmic sperm injection (ICSI) for non–male factor indications: a Committee opinion</source>. <volume>114</volume>. <publisher-loc>Birmingham, Alabama</publisher-loc>: <publisher-name>American Society for Reproductive Medicine</publisher-name>, <year>2020</year>: <fpage>239</fpage>–<lpage>45</lpage>.</mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Practice Committee of Society for Assisted Reproductive Technology</collab>, <collab>Practice Committee of American Society for Reproductive Medicine</collab></person-group>. <article-title>Elective single-embryo transfer</article-title>. <source>Fertil Steril</source><year>2012</year>;<volume>97</volume>:<fpage>835</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2011.11.050</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22196716?><pub-id pub-id-type="pmid">22196716</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org</collab>, <collab>Practice Committee of the Society for Assisted Reproductive Technology</collab></person-group>. <article-title>Guidance on the limits to the number of embryos to transfer: a committee opinion</article-title>. <source>Fertil Steril</source><year>2017</year>;<volume>107</volume>:<fpage>901</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2017.02.107</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28292618?><pub-id pub-id-type="pmid">28292618</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boivin</surname><given-names>J</given-names></string-name>, <string-name><surname>Takefman</surname><given-names>J</given-names></string-name>, <string-name><surname>Braverman</surname><given-names>A</given-names></string-name></person-group>. <article-title>The fertility quality of life (FertiQoL) tool: development and general psychometric properties</article-title>. <source>Fertil Steril</source><year>2011</year>;<volume>96</volume>:<fpage>409</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2011.02.046</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21458806?><pub-id pub-id-type="pmid">21458806</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
